Jonas O. Petersen

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Harnessing PPAR pharmacology through dual incretin-directed delivery.

Harnessing PPAR pharmacology through dual incretin-directed delivery.

Journal: Cell metabolism

Published: April 03, 2026

The evolving landscape of obesity pharmacotherapy.

The evolving landscape of obesity pharmacotherapy.

Journal: Nature reviews. Drug discovery

Published: March 17, 2026

Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy.

Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy.

Journal: Cell

Published: February 25, 2025

SnapShot: Brain-targeting anti-obesity medications.

SnapShot: Brain-targeting anti-obesity medications.

Journal: Cell metabolism

Published: February 06, 2025

Maximal Strength Testing Using the Long-Lever Hip Adduction Squeeze Test in Youth Elite Football (Soccer) Players: A Four-Week Reliability Study.

Maximal Strength Testing Using the Long-Lever Hip Adduction Squeeze Test in Youth Elite Football (Soccer) Players: A Four-Week Reliability Study.

Journal: International journal of sports physical therapy

Published: December 13, 2024

Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice.

Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice.

Journal: Molecular metabolism

Published: June 24, 2024

Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment.

Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment.

Journal: Science advances

Published: March 01, 2024

GLP-1-directed NMDA receptor antagonism for obesity treatment.

GLP-1-directed NMDA receptor antagonism for obesity treatment.

Journal: Nature

Published: November 23, 2022

GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity.

GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity.

Journal: Cell reports

Published: October 05, 2022

Structure-Activity Studies of 3,9-Diazaspiro[5.5]undecane-Based γ-Aminobutyric Acid Type A Receptor Antagonists with Immunomodulatory Effect.

Structure-Activity Studies of 3,9-Diazaspiro[5.5]undecane-Based γ-Aminobutyric Acid Type A Receptor Antagonists with Immunomodulatory Effect.

Journal: Journal of medicinal chemistry

Published: December 15, 2021

Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities.

Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities.

Journal: Drugs

Published: June 28, 2019

Correction: Gold-carbonyl group interactions in the electrochemistry of anthraquinone thiols self-assembled on Au(111)-surfaces.

Correction: Gold-carbonyl group interactions in the electrochemistry of anthraquinone thiols self-assembled on Au(111)-surfaces.

Journal: Chemical science

Published: May 01, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026